About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Eli Lily shares. Let's have a look at those after that news that we just uh reported that the pharma giant released more data on its obesity pill. Patients with obesity and diabetes lost about 10.5% of their body weight.The data clears the way for Lily to seek regulatory approval. Shares are up 1.7% when they got some data on this a month or so ago or just under a month ago they did fall. Let's get clarity on which bit of the data outweighs the other.Tim Anderson, Bank of America Security senior pharma anal ...

Joining us now to discuss the new developments is Dr. . Angela Fitch. She is a primary care clinician and the past president of the Obesity Medicine Association.Dr. . Fitch, welcome. >> Thank you for having me.>> So, we've been seeing GLP1s everywhere, Dr. . Fitch, but injectables. Now, we have the potential of this pill hitting the market with this drug trial with Eli Liy.What is it and how is it affecting folks. >> So, the other GLP ones we have, they're very hard to get into the system orally. That's why ...